Viyash Scientific Ltd Upgraded to Buy on Strong Financial and Technical Performance

Financial Performance Drives Upgrade

The primary catalyst behind the upgrade is Viyash Scientific’s very positive financial trend observed in the quarter ended June 2026. The company’s financial grade has improved from outstanding to very positive, despite a slight dip in its financial score from 34 to 27 over the past three months. Key financial metrics underpinning this upgrade include an operating profit to interest ratio reaching a robust 14.26 times, signalling strong earnings relative to interest expenses. Profit before tax (excluding other income) surged by 143.51% to ₹104.10 crores, while net sales hit a record quarterly high of ₹946.36 crores.

Additionally, the company’s debt-equity ratio has fallen to a low 0.17 times, reflecting a conservative capital structure and reduced financial risk. Cash and cash equivalents also stand at a healthy ₹269.71 crores, providing ample liquidity. Net profit after tax (PAT) reached ₹65.87 crores, the highest recorded in recent quarters, underscoring operational efficiency and profitability.

However, some challenges remain, such as a low debtors turnover ratio of 3.27 times, which may indicate slower collection cycles and potential working capital inefficiencies. Despite this, the overall financial health is markedly improved, justifying the upgrade in the financial trend assessment.

Quality Metrics Show Improvement to Average

Viyash Scientific’s quality grade has been upgraded from below average to average, reflecting steady improvements in its operational and financial efficiency over the medium term. The company has demonstrated a healthy five-year sales growth rate of 20.85% and an EBIT growth rate of 28.24%, indicating strong top-line and operating profit expansion. The average EBIT to interest coverage ratio stands at 2.30, suggesting adequate ability to service debt from earnings.

Despite a relatively high average debt to EBITDA ratio of 9.68, the net debt to equity ratio remains moderate at 0.46, signalling manageable leverage. The company’s sales to capital employed ratio is 1.37, reflecting reasonable asset utilisation. Tax ratio is stable at 35.34%, and importantly, there are no pledged shares, which reduces concerns over promoter encumbrances. Institutional holding is modest at 8.26%, though it has declined recently, which may warrant monitoring.

Return on capital employed (ROCE) averages 6.09%, while return on equity (ROE) is low at 4.59%, highlighting room for improvement in generating shareholder returns. Compared to peers such as Gland Pharma and Emcure Pharma, which hold good quality grades, Viyash Scientific’s average rating suggests it is on a positive trajectory but still has some operational efficiencies to enhance.

Valuation Moves from Expensive to Fair

The valuation grade for Viyash Scientific has shifted favourably from expensive to fair, reflecting a more balanced price relative to earnings and book value. The company’s price-to-earnings (PE) ratio stands at 48.85, which, while elevated, is reasonable given its growth prospects and sector norms. Price-to-book value is 4.03, and enterprise value to EBITDA is 16.78, both indicating a fair valuation compared to more expensive peers in the pharmaceuticals and biotechnology sector.

The PEG ratio of 1.15 suggests that the stock’s price is aligned with its earnings growth, supporting the fair valuation assessment. Latest ROCE and ROE figures of 13.36% and 7.11% respectively further justify this valuation, as the company is generating returns that merit investor interest without appearing overvalued. This re-rating from expensive to fair valuation improves the stock’s attractiveness for long-term investors seeking growth at a reasonable price.

Technical Indicators Turn Bullish

On the technical front, Viyash Scientific’s trend has improved from mildly bullish to bullish, signalling positive momentum in the stock price. Daily moving averages are bullish, supported by monthly and weekly bullish signals from the KST (Know Sure Thing) indicator. Bollinger Bands show a mildly bullish stance on the weekly chart and bullish on the monthly chart, suggesting expanding price volatility in an upward direction.

While the MACD indicator is mildly bearish on the weekly timeframe, it remains bullish monthly, indicating some short-term consolidation but longer-term strength. Relative Strength Index (RSI) shows no significant signals, and Dow Theory trends remain neutral. On-balance volume (OBV) is mildly bearish weekly but neutral monthly, reflecting mixed volume trends. Overall, the technical picture supports a positive outlook, complementing the fundamental upgrades.

Long-Term Growth and Market Performance

Viyash Scientific has demonstrated strong long-term growth, with net sales growing at an annualised rate of 20.85% and operating profit expanding at 28.24% over five years. The company has reported positive results for ten consecutive quarters, highlighting consistent operational execution. Net profit growth of 115.17% in the latest quarter further underscores this momentum.

In terms of market returns, the stock has outperformed the Sensex significantly over multiple periods. Year-to-date, Viyash Scientific has delivered a 28.01% return compared to the Sensex’s negative 8.38%. Over one year, the stock returned 55.27% versus the Sensex’s -3.05%, and over three years, it surged 190.79% against the Sensex’s 19.53%. This consistent outperformance reflects strong investor confidence and robust business fundamentals.

Risks and Considerations

Despite the positive upgrade, investors should be mindful of certain risks. The company’s average ROE of 4.59% indicates relatively low profitability per unit of shareholder equity, suggesting scope for improved management efficiency. The debt to EBITDA ratio remains elevated at 0.75 times, which could constrain financial flexibility if earnings falter.

Institutional investor participation has declined by 2.67% in the previous quarter, with current holdings at 8.26%. Reduced institutional interest may reflect concerns over growth sustainability or valuation, and investors should monitor any further changes in shareholding patterns. Additionally, the low debtors turnover ratio points to potential working capital challenges that could impact cash flow.

Overall, while the upgrade to Buy is well supported by improved financials, fair valuation, and bullish technicals, investors should weigh these risks carefully within their portfolio strategy.

Conclusion

Viyash Scientific Ltd’s upgrade from Hold to Buy is driven by a combination of very positive financial results, improved quality metrics, a fairer valuation profile, and strengthening technical indicators. The company’s strong quarterly performance, consistent growth, and market outperformance position it favourably within the pharmaceuticals and biotechnology sector. While some operational and financial risks remain, the overall outlook is constructive, making Viyash Scientific an attractive proposition for investors seeking exposure to a small-cap stock with solid fundamentals and growth potential.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →